(Press-News.org) SAN FRANCISCO—People with an underactive thyroid may have an increased risk of developing small intestinal bacterial overgrowth (SIBO), a risk that may be reduced with thyroid hormone treatment, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
“We now know that people with hypothyroidism, especially those with autoimmune thyroiditis, are more likely to develop SIBO, but this risk appear to be mitigated in those taking thyroid medications,” said Ruchi Mathur, M.D., Director of the Diabetes Outpatient Treatment and Education Center and Director of Clinical Operations of Medically Associated Science and Technology, at Cedars-Sinai in Los Angeles, Calif.
Mathur said their research also suggests there may be a microbiological mechanism driving this association, which could lead to more personalized treatments.
The researchers investigated the relationship between SIBO and hypothyroidism in people older than 18 who previously underwent upper endoscopy without colon prep and reported living with hypothyroidism as well as controls. Subjects were recruited through their flagship REIMAGINE study.
They analyzed small bowel fluid samples from 49 people with hypothyroidism and 323 without the condition and performed DNA sequencing to identify microbial species. The results showed that people with hypothyroidism had a significantly higher prevalence of SIBO compared to controls (33% vs. 15%).
Mathur and colleagues then further evaluated four groups: SIBO-positive with hypothyroidism, SIBO-negative with hypothyroidism, SIBO-positive without thyroid disease, and SIBO-negative without thyroid disease.
The analysis showed different patterns of bacteria in the gut depending on a person’s thyroid status and co-occurrence of SIBO.
Separately, they performed a large-scale analysis of medical records from the TriNetX database, which looked at the 10-year risks of developing SIBO in people with hypothyroidism or autoimmune thyroiditis compared to matched controls. The risks were also mitigated in people taking levothyroxine.
“Results showed the risk of developing SIBO in subjects with hypothyroidism is 2.2 times more than the risk in a matched control cohort and was 2.4 times higher in those with autoimmune thyroiditis compared to a matched control group. This echoes our findings in the REIMAGINE cohort,” noted the study’s presenting author, Margaret Wei, M.D., of the Cedars-Sinai Medical Center Endocrine Fellowship Program.
“These findings open the door to new screening and prevention strategies. For example, doctors may begin to monitor thyroid health more closely in patients with SIBO, and vice versa. It also supports the idea that improving gut health could have far-reaching effects beyond digestion, possibly even helping to prevent autoimmune diseases, such as Hashimoto’s,” Mathur said. “As research continues, this could lead to more personalized care and earlier interventions for at-risk individuals.”
# # #
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
END
SAN FRANCISCO—Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide treatment alone, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
“These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women,” said Regina Castaneda, ...
SAN FRANCISCO—Metabolic health factors, including small increases in blood sugar, are the main drivers of change in the reproductive systems and sexual functioning of aging men, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
“Although age and testosterone levels have long been considered an impetus for men’s declining sexual health, our research indicates that these changes more closely correlate with modest increases in blood sugar and other metabolic changes,” said Michael Zitzmann, ...
SAN FRANCISCO—Strong emotional links between children with chronic conditions and their family caregivers suggest that improving parent well-being may directly benefit a child’s overall health and coping mechanisms, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
The study observed children with growth hormone deficiency and their caregivers to better understand the impact that physical or emotional distress can have. Findings suggest that when parents or caregivers of children with growth hormone deficiency report symptoms of stress, anxiety and depression, so does the child they ...
SAN FRANCISCO—Oxytocin, often called “the love hormone,” may play a protective role in mood disturbances triggered by sleep loss and hormonal shifts during key reproductive transitions like postpartum and menopause, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
Researchers at Brigham and Women’s Hospital and Harvard Medical School studied the combined impact of sleep interruption and estrogen suppression on mood and oxytocin levels in healthy premenopausal women. Their findings suggest that oxytocin may help reduce the negative mood effects brought on by fragmented sleep, which ...
SAN FRANCISCO—The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
"Obesity is a significant risk factor for breast cancer, and while it is very preliminary data, our studies in mice suggest that these new anti-obesity drugs may be a way to reduce obesity-associated breast cancer risk or improve outcomes,” said study author Amanda Kucinskas, ...
https://doi.org/10.1016/j.apsb.2025.05.003
This new article publication from Acta Pharmaceutica Sinica B, discusses how a CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury.
Acute liver injury (ALI) serves as a critical precursor and major etiological factor in the progression and ultimate manifestation of various hepatic disorders. The prevention and treatment of ALI is still a serious global challenge. Given the limited therapeutic options for ALI, exploring novel targeted therapeutic agents becomes imperative. The potential therapeutic ...
https://doi.org/10.1016/j.apsb.2025.05.018
This new article publication from Acta Pharmaceutica Sinica B, discusses how melatonin receptor 1a alleviates sleep fragmentation-aggravated testicular injury in T2DM by suppression of TAB1/TAK1 complex through FGFR1.
A major obstacle in type 2 diabetes mellitus (T2DM) is sleep fragmentation (SF), which negatively affects testicular function. However, the underlying mechanisms remain to be elucidated. This study demonstrated that SF induces testicular damage through a mechanism involving lipid metabolism, ...
https://doi.org/10.1016/j.apsb.2025.05.013
This new article publication from Acta Pharmaceutica Sinica B, discusses how single-cell RNA sequencing reveals that Shen-Bai-Jie-Du decoction retards colorectal tumorigenesis by regulating the TMEM131–TNF signaling pathway-mediated differentiation of immunosuppressive dendritic cells.
Colorectal tumorigenesis generally progresses from adenoma to adenocarcinoma, accompanied by dynamic changes in the tumor microenvironment (TME). A randomized controlled trial has confirmed the efficacy and safety of Shen-Bai-Jie-Du decoction (SBJDD) in preventing colorectal ...
https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b/vol/15/issue/7
Acta Pharmaceutica Sinica B (APSB) was founded with the goal of creating a global high-level forum centred around drug discovery and pharmaceutical research/application. APSB was included by Chemical Abstracts in 2011, accepted by PubMed Central in 2015, indexed by Science Citation Index in 2017 and has evolved to become one of the most important international journals in the field of pharmaceutical sciences.
APSB is a monthly journal, in English, which publishes ...
In a first for the field, researchers from The Grainger College of Engineering at the University of Illinois Urbana-Champaign have reported a photopumped lasing from a buried dielectric photonic-crystal surface-emitting laser emitting at room temperature and an eye-safe wavelength. Their findings, published in IEEE Photonics Journal, improve upon current laser design and open new avenues for defense applications.
For decades, the lab of Kent Choquette, professor of electrical and computer engineering, have explored VCSELs, a type of surface-emitting laser used in common technology like smartphones, laser printers, barcode scanners, and even vehicles. But ...
